Evidence map›Paper›PMID 39080625›Full record

ArticleBMC medical imaging2024

A comparative study of

Zhenyan Ye, Ying Kou, Jiaqi Shen, Jun Dang, Xiaofei Tan, Xiao Jiang, Xiaoxiong Wang, Hao Lu, Shirong Chen, Zhuzhong Cheng

Erratum issuedAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Zhenyan YeDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Ying KouDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Jiaqi ShenDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Jun DangDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Xiaofei TanDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Xiao JiangDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Xiaoxiong WangDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Hao LuDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Shirong ChenDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Zhuzhong ChengDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. chengzhuzhong@163.com.

Funding

Sichuan Cancer Hospital outstanding youth Fund YB.2021029Sichuan Cancer Hospital Outstanding Youth Funding YB 2023022Sichuan Provincial Science and Technology Department Project No.2022YFS0068
6 · The paper itself

Abstract

purposeTo evaluate the difference in the diagnostic efficacy of

methodsA total of 41 patients with suspected prostate cancer who underwent

resultsCompared with histopathological results, the sensitivity, PPV and diagnostic accuracy of

conclusionCompared with MRI,

Indexed as

Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstate-Specific AntigenProstatic NeoplasmsAgedFluorine RadioisotopesHumansMaleMiddle AgedNiacinamideOligopeptidesRadiopharmaceuticalsRetrospective StudiesSensitivity and SpecificityFluorine RadioisotopesNiacinamideOligopeptidesProstate-Specific AntigenPSMA-1007Radiopharmaceuticals18F-PSMA-1007Gleason scoreMetabolic parametersMolecular expressionMRIPET/CTProstate cancer

Identifiers

PMID39080625
PMCPMC11290235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.